ArticleJAMA oncology2019
Treatment-Related Complications of Systemic Therapy and Radiotherapy.
Article in JAMA oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07164534 (A Phase III Trial to Assess the Effectiveness of NRF2 Activator), which is not on this map. Cited by 67 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity. (CHOC-LATE Trial)
Who cites it
67 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Accuracy of Radiomics-Based Machine Learning for Predicting Risk of Recurrence in Non-Small Cell Lung Cancer: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- Synergistic antitumor effects ofFrontiers in pharmacology · 2025Pooled it
- Systemic therapy and radiotherapy related complications and subsequent hospitalisation rates: a systematic review.BMC cancer · 2024Pooled it
- MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- Unplanned hospital presentations in oncology patients receiving chemotherapy: a secondary analysis of a randomized controlled trial to explore opportunities for improving supportive care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Trial
- Safety and efficacy of PEG-rhG-CSF as primary prophylaxis for neutropenia in gastrointestinal cancer patients receiving combination chemotherapy including oral agents: a prospective, exploratory, non-randomized controlled study.Frontiers in oncology · 2026Trial
- Healthcare provider evaluation of machine learning-directed care: reactions to deployment on a randomised controlled study.BMJ health & care informatics · 2023Trial
- Self-efficacy as a mediator between digital health literacy and self-care behaviors in older adults with cancer undergoing chemotherapy.Asia-Pacific journal of oncology nursing · 2026Article
- Chronic liver diseases aggravate radiation-induced intestinal injury through taurocholic acid dysregulation.Journal of translational medicine · 2026Article
- Synthesis and characterization of bifunctional nanoprobes for targeted photodynamic therapy in breast cancer treatment.Discover nano · 2026Article
- Clinical outcomes of synthetic absorbable mesh use in breast surgery: First case series in reconstruction and aesthetic mastopexy.JPRAS open · 2026Article
- US Food and Drug Administration black box warnings: Characteristics of drug classes and adverse effects.The Journal of pharmacology and experimental therapeutics · 2026Article
- Delaying cancer progression by integrating toxicity constraints in a model of adaptive therapy.NPJ systems biology and applications · 2026Article
- Real-World Determinants of Olanzapine Prescribing for Antiemetic Prophylaxis in Adults Receiving Highly-Emetogenic Chemotherapy.Hospital pharmacy · 2025Article
- Employment Disruption and Financial Burden Associated with Gastrointestinal Cancers.Annals of surgical oncology · 2025Article
- ASO Author Reflections: Employment Disruption and Financial Burden Associated with Gastrointestinal Cancers.Annals of surgical oncology · 2025Article
- Post-Traumatic Stress and Stressor-Related Disorders in Hematological Malignancies: A Review.Journal of clinical medicine · 2025Review
- Incidence and risk factors of pneumonitis in ALK-rearranged non-small cell lung cancer patients treated with alectinib and thoracic radiotherapy.Translational lung cancer research · 2025Article
- Colorectal Cancer: Therapeutic Approaches and Their Complications.Biomedicines · 2025Review
- Patterns in Symptoms Preceding Acute Care in Patients With Cancer.JAMA network open · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
importanceSystemic therapy and radiotherapy can be associated with acute complications that may require emergent care. However, there are limited data characterizing complications and the financial burden of cancer therapy that are treated in emergency departments (EDs) in the United States.
objectivesTo estimate the incidence of treatment-related complications of systemic therapy or radiotherapy, examine factors associated with inpatient admission, and investigate the overall financial burden. DESIGN, SETTING, AND
participantsA retrospective analysis of the Healthcare Cost and Utilization Project Nationwide Emergency Department Sample was performed. Between January 2006 and December 2015, there was a weighted total of 1.3 billion ED visits; of these, 1.5 million were related to a complication of systemic therapy or radiotherapy for cancer. Data analysis was conducted from February 22 to December 23, 2018. External cause of injury codes, Clinical Classifications Software, International Classification of Diseases, Ninth Revision, Clinical Modification, and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10), Clinical Modification codes were used to identify patients with complications of systemic therapy or radiotherapy. MAIN OUTCOMES AND MEASURES: Patterns in treatment-related complications, patient- and hospital-related factors associated with inpatient admission, and median and total charges for treatment-related complications were the main outcomes.
resultsOf the 1.5 million ED visits included in the analysis, 53.2% of patients were female and mean age was 63.3 years. Treatment-related ED visits increased by a rate of 10.8% per year compared with 2.0% for overall ED visits. Among ED visits, 90.9% resulted in inpatient admission to the hospital and 4.9% resulted in death during hospitalization. Neutropenia (136 167 [8.9%]), sepsis (128 171 [8.4%]), and anemia (117 557 [7.7%]) were both the most common and costliest (neutropenia: $5.52 billion; sepsis: $11.21 billion; and anemia: $6.78 billion) complications diagnosed on presentation to EDs; sepsis (odds ratio [OR], 21.00; 95% CI, 14.61-30.20), pneumonia (OR, 9.73; 95% CI, 8.08-11.73), and acute kidney injury (OR, 9.60; 95% CI, 7.77-11.85) were associated with inpatient admission. Costs related to the top 10 most common complications totaled $38 billion and comprised 48% of the total financial burden of the study cohort. CONCLUSIONS AND RELEVANCE: Emergency department visits for complications of systemic therapy or radiotherapy increased at a 5.5-fold higher rate over 10 years compared with overall ED visits. Neutropenia, sepsis, and anemia appear to be the most common complications; sepsis, pneumonia, and acute kidney injury appear to be associated with the highest rates of inpatient admission. These complications suggest that significant charges are incurred on ED visits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.